Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16254590 | 0.95 | KMT2A (0.65) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22838012 | 0.93 | KMT2A (0.63) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL425352 | 0.90 | RAB9A (0.60) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11470310 | 0.86 | KMT2A (0.81) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19145900 | 0.84 | KMT2A (0.64) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12962115 | 0.83 | KMT2A (0.68) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14365834 | 0.83 | KMT2A (1.00) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10370837 | 0.83 | KMT2A (0.67) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10371086 | 0.83 | KMT2A (0.67) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12017882 | 0.82 | KMT2A (0.66) | KMT2ATSHRRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021146629-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20200407470-A1 | METHODS OF SYNTHESIS OF HOMOPOLYMERS AND NON-HOMOPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES IN AN AQUEOUS MEDIUM | ISP INVESTMENTS LLC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10844154-B2 | Proliferous copolymers comprising lactamic moieties | ISP INVESTMENTS LLC (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020210828-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020150674-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
| US-10632059-B2 | Non-aqueous compositions of polymers derived from monomers having acryloyl moiety and lactam moiety and applications thereof | ISP INVESTMENTS LLC (US) | 2020-04-28 | — | — | US | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-2809652-B1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | disclosed |
| EP-2964617-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-20160024251-A1 | THERMORESPONSIVE POLYESTERS | THE UNIVERSITY OF AKRON | 2016-01-28 | — | — | US | disclosed |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | KMT2A 761/4885TSHR 4506/4885RAB9A 2490/4885 |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | NQO1, NDUFC2, NDUFV2 | KMT2A 1732/4885TSHR 2798/4885RAB9A 909/4885 |
| US-10632059-B2 | Non-aqueous compositions of polymers derived from monomers having acryloyl moiety and lactam moiety and applications thereof | C9, PARG, C5 | KMT2A 3840/4885TSHR 4135/4885RAB9A 3191/4885 |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | KMT2A 2807/4885TSHR 655/4885RAB9A 2816/4885 |
| US-10844154-B2 | Proliferous copolymers comprising lactamic moieties | PCNA, MKI67, CCNA1 | KMT2A 1923/4885TSHR 4126/4885RAB9A 4179/4885 |
| US-20160024251-A1 | THERMORESPONSIVE POLYESTERS | COASY, CD14, NCAPH | KMT2A 2313/4885TSHR 4068/4885RAB9A 2288/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | KMT2A 761/4885TSHR 4506/4885RAB9A 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.